BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Antibodies
Newco news

Sixpeaks launches to advance its dual activin IIA/B antibody

May 31, 2024
By Nuala Moran
Obesity specialist Sixpeaks Bio AG emerged from stealth with $110 million in funding and an option to be acquired by Astrazeneca plc within the next two years, subject to filing an IND for the lead product.
Read More

Financings for May 31, 2024

May 31, 2024
Biopharmas raising money in public or private financings, including: Aim, Aptose, Calidi, Celcuity, Cinrx, OS Therapies.
Read More

Financings for May 31, 2024

May 31, 2024
Med-tech firms raising money in public or private financings, including: Valar Labs.
Read More

Merus raising $400M; petosemtamab scores in head and neck cancer

May 30, 2024
By Karen Carey
After shares climbed 36% on May 24 following the release of an American Society of Clinical Oncology abstract detailing an impressive phase II overall response rate in first-line head and neck cancer with bispecific antibody petosemtamab in combination with pembrolizumab, Merus NV is raising $400.2 million in an upsized follow-on offering.
Read More

Financings for May 30, 2024

May 30, 2024
Med-tech firms raising money in public or private financings, including: Biosig Technologies, Bruker, Medtronic.
Read More
Rebound arrows

2024: A rebound year for private investments in public equity

May 29, 2024
By Amanda Lanier
Following a significant decline in 2023, private investments in public equity (PIPEs) are rebounding strongly in 2024. Through late May, the collective value of PIPEs has already surpassed the full year 2023 by more than three times, and is also ahead of 2022.
Read More

Financings for May 29, 2024

May 29, 2024
Biopharmas raising money in public or private financings, including: Adcendo, Avelos, Cytokinetics, Expressionedits, Gameto, Insmed, Lambdavision, Matter Bio, Merus.
Read More

Financings for May 29, 2024

May 29, 2024
Med-tech firms raising money in public or private financings, including: Boryung, Lambdavision.
Read More

Financings for May 28, 2024

May 28, 2024
Biopharmas raising money in public or private financings, including: Actuate, Boost, Dyne, Enlivex, Genelux, Lucy, Reviva.
Read More

Financings for May 28, 2024

May 28, 2024
Med-tech firms raising money in public or private financings, including: Venus Concept.
Read More
Previous 1 2 … 167 168 169 170 171 172 173 174 175 … 652 653 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing